Ionis Pharmaceuticals, Inc. (IONS)
Ionis Pharmaceuticals, Inc. (IONS) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Ionis Q4 Earnings & Sales Beat, Stock Down on Soft 2026 Outlook
IONS beats Q4 estimates on strong Tryngolza sales, but shares slip 5% as 2026 revenue outlook and slower uptake for new drugs weigh on sentiment.
Ionis Pharmaceuticals (IONS) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares to a loss of $0.66 per share a year ago.
Ionis Pharmaceuticals, Inc. (IONS) Q4 2025 Earnings Call Transcript
Ionis Pharmaceuticals, Inc. (IONS) Q4 2025 Earnings Call Transcript
Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPS
Besides Wall Street's top-and-bottom-line estimates for Ionis Pharmaceuticals (IONS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema
IONS secures EU approval for Dawnzera in hereditary angioedema, after FDA clearance in the United States in August last year.
Ionis: Expected 2026 Launch Of Olezarsen In SHTG To Spur Leap In Revenue Growth
Ionis Pharmaceuticals (IONS) has appreciated ~25% since my last upgrade, reflecting strong momentum. This article spotlights Olezarsen, Ionis's wholly owned molecule, as a key driver of future upside. Recent approvals and upcoming catalysts underpin the bullish investment thesis for IONS.
Ionis Pharmaceuticals, Inc. (IONS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at Stifel 2025 Healthcare Conference Transcript
Ionis Pharmaceuticals, Inc. ( IONS ) Stifel 2025 Healthcare Conference November 13, 2025 8:00 AM EST Company Participants Kyle Jenne - Executive VP & Chief Global Product Strategy Officer Elizabeth L. Hougen - Executive VP of Finance & CFO Conference Call Participants Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Paul Matteis Stifel, Nicolaus & Company, Incorporated, Research Division Good morning.
Ionis Pharmaceuticals, Inc. (IONS) Discusses Detailed Phase III Results for Olezarsen in Severe Hypertriglyceridemia Transcript
Ionis Pharmaceuticals, Inc. ( IONS ) Discusses Detailed Phase III Results for Olezarsen in Severe Hypertriglyceridemia November 8, 2025 3:00 PM EST Company Participants D. Walke - Senior Vice President of Investor Relations Brett Monia - Founder, CEO & Director Sotirios Tsimikas - Senior Vice President of Global Cardiovascular Development Kyle Jenne - Executive VP & Chief Global Product Strategy Officer Conference Call Participants Jay Olson - Oppenheimer & Co. Inc., Research Division Mani Foroohar - Leerink Partners LLC, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Debjit Chattopadhyay - Guggenheim Securities, LLC, Research Division Denis Reznik - Raymond James & Associates, Inc., Research Division Zaki Molvi - Jefferies LLC, Research Division Tommie Reerink - Goldman Sachs Group, Inc., Research Division Yanan Zhu - Wells Fargo Securities, LLC, Research Division Julian Pino - Stifel, Nicolaus & Company, Incorporated, Research Division Luca Issi - RBC Capital Markets, Research Division Myles Minter - William Blair & Company L.L.C.
